speb/financial-data huggingface dataset:
DR.TO income_statement (annual, 2024-12-31) — Salaries And Wages: 65747000.00
DR.TO cash_flow (annual, 2024-12-31) — Sale Of Business: 92487000.00
DR.TO cash_flow (quarterly, 2024-12-31) — Sale Of Business: 92487000.00
DR.TO income_statement (annual, 2024-12-31) — Selling General And Administration: 116590000.00
DR.TO balance_sheet (annual, 2024-12-31) — Share Issued: 23023762.00
DR.TO income_statement (annual, 2024-12-31) — Special Income Charges: -2265000.00
DR.TO income_statement (quarterly, 2024-12-31) — Special Income Charges: -2265000.00
DR.TO cash_flow (annual, 2024-12-31) — Stock Based Compensation: -246000.00
DR.TO cash_flow (quarterly, 2024-12-31) — Stock Based Compensation: -272000.00
DR.TO balance_sheet (annual, 2024-12-31) — Stockholders Equity: 122019000.00
DR.TO balance_sheet (annual, 2024-12-31) — Tangible Book Value: 24193000.00
DR.TO income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -8850.00
DR.TO income_statement (annual, 2024-12-31) — Tax Provision: -6014000.00
DR.TO income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.15
DR.TO balance_sheet (annual, 2024-12-31) — Taxes Receivable: 87000.00
DR.TO cash_flow (annual, 2024-12-31) — Taxes Refund Paid: -6323000.00
DR.TO balance_sheet (annual, 2024-12-31) — Total Assets: 346294000.00
DR.TO balance_sheet (annual, 2024-12-31) — Total Capitalization: 145852000.00
DR.TO balance_sheet (annual, 2024-12-31) — Total Debt: 73937000.00
DR.TO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 147452000.00
DR.TO income_statement (annual, 2024-12-31) — Total Expenses: 193718000.00
DR.TO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 198842000.00
DR.TO balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 180959000.00
DR.TO balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 109893000.00
DR.TO income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 52370000.00
DR.TO income_statement (annual, 2024-12-31) — Total Other Finance Cost: 244000.00
DR.TO balance_sheet (annual, 2024-12-31) — Total Tax Payable: 13766000.00
DR.TO income_statement (annual, 2024-12-31) — Total Unusual Items: -59000.00
DR.TO income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -59000.00
DR.TO balance_sheet (annual, 2024-12-31) — Working Capital: 76386000.00
DR.TO income_statement (annual, 2024-12-31) — Write Off: 0.00
DR.TO income_statement (quarterly, 2024-12-31) — Write Off: 0.00
DR.TO income_statement (quarterly, 2025-03-31) — +Operating Expense: 31597000.00
DR.TO income_statement (quarterly, 2025-03-31) — +Total Revenue: 60557000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 13410000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 39682000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 470000.00
DR.TO income_statement (quarterly, 2025-03-31) — Amortization: 133000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Amortization Cash Flow: 133000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Amortization Of Intangibles: 133000.00
DR.TO income_statement (quarterly, 2025-03-31) — Amortization Of Intangibles Income Statement: 133000.00
DR.TO income_statement (quarterly, 2025-03-31) — Average Dilution Earnings: 0.00
DR.TO income_statement (quarterly, 2025-03-31) — Basic Average Shares: 22176712.00
DR.TO income_statement (quarterly, 2025-03-31) — Basic EPS: 0.17
DR.TO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 108496000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -785000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 37731000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Capital Stock: 272926000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 65724000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 65724000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -1441000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -57612000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -785000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 15755000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -3530000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -3522000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Change In Inventory: -299000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Change In Payable: -3530000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -7052000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 1179000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Change In Receivables: 5786000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -386000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: 5786000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Changes In Cash: -42642000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Common Stock: 272926000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Common Stock Dividend Paid: -1441000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 80528000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -45785000.00
DR.TO income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 18302000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 17287000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Current Assets: 115948000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 8708000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Current Debt: 10273000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 18981000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 80060000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -321000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Deferred Tax: -321000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Depreciation: 4135000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 4268000.00
DR.TO income_statement (quarterly, 2025-03-31) — Depreciation Amortization Depletion Income Statement: 2932000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 4268000.00
DR.TO income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 2932000.00
DR.TO income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 2799000.00
DR.TO income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 22176712.00
DR.TO income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.17
DR.TO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 3728000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 1218000.00
DR.TO income_statement (quarterly, 2025-03-31) — EBIT: 11512000.00
DR.TO income_statement (quarterly, 2025-03-31) — EBITDA: 15780000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: -130000.00
DR.TO cash_flow (quarterly, 2025-03-31) — End Cash Position: 65724000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -57612000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 14970000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of Business: 0.00
DR.TO income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: -130000.00
DR.TO income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 28665000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Goodwill: 90600000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 97693000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Gross PPE: 80188000.00
DR.TO income_statement (quarterly, 2025-03-31) — Gross Profit: 42255000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Income Tax Payable: 14254000.00
DR.TO income_statement (quarterly, 2025-03-31) — Interest Expense: 5094000.00
DR.TO income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 5094000.00
DR.TO income_statement (quarterly, 2025-03-31) — Interest Income: 1039000.00
DR.TO income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 1039000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Interest Paid Cfo: -1139000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Inventory: 6104000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Invested Capital: 113903000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -785000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 29023000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 23102000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 52125000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -3889000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Minority Interest: 24188000.00
DR.TO income_statement (quarterly, 2025-03-31) — Minority Interests: -5252000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: 0.00
DR.TO cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: -45785000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 130000.00
DR.TO income_statement (quarterly, 2025-03-31) — Net Income: 3728000.00
DR.TO income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 3728000.00
DR.TO income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 7052000.00
DR.TO income_statement (quarterly, 2025-03-31) — Net Income Discontinuous Operations: 1928000.00
DR.TO income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 3728000.00
DR.TO income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1800000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 8980000.00
DR.TO income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 8980000.00
DR.TO income_statement (quarterly, 2025-03-31) — Net Interest Income: -4110000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
DR.TO cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -3889000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -3889000.00
DR.TO income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -4110000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -6497000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Net PPE: 80188000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -785000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -17165000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 16000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 15111000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 16000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 15111000.00
DR.TO income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 15910000.00
DR.TO income_statement (quarterly, 2025-03-31) — Normalized Income: 1910500.00
DR.TO cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 15755000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 130000.00
DR.TO income_statement (quarterly, 2025-03-31) — Operating Income: 10658000.00
DR.TO income_statement (quarterly, 2025-03-31) — Operating Revenue: 60557000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 19466849.00
DR.TO cash_flow (quarterly, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: 0.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 10273000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 14910000.00
DR.TO income_statement (quarterly, 2025-03-31) — Other Gand A: 12330000.00
DR.TO income_statement (quarterly, 2025-03-31) — Other Income Expense: -130000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 7093000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 4193000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 41833000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Other Properties: 80188000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Other Receivables: 4300000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Payables: 28882000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 46169000.00
DR.TO income_statement (quarterly, 2025-03-31) — Pretax Income: 6418000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -785000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Raw Materials: 6104000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Receivables: 44120000.00
DR.TO income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 16966000.00
DR.TO income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 4268000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -3889000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -45785000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -192868000.00
DR.TO income_statement (quarterly, 2025-03-31) — Salaries And Wages: 16335000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Sale Of Business: 0.00
DR.TO cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 0.00
DR.TO income_statement (quarterly, 2025-03-31) — Selling General And Administration: 28665000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Share Issued: 19466849.00
DR.TO cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 0.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 80528000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -17165000.00
DR.TO income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -19500.00
DR.TO income_statement (quarterly, 2025-03-31) — Tax Provision: -634000.00
DR.TO income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.15
DR.TO balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 138000.00
DR.TO cash_flow (quarterly, 2025-03-31) — Taxes Refund Paid: 30000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Total Assets: 293845000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 103630000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Total Debt: 71106000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 104716000.00
DR.TO income_statement (quarterly, 2025-03-31) — Total Expenses: 49899000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 189129000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 177897000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 109069000.00
DR.TO income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 10658000.00
DR.TO income_statement (quarterly, 2025-03-31) — Total Other Finance Cost: 55000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 14254000.00
DR.TO income_statement (quarterly, 2025-03-31) — Total Unusual Items: -130000.00
DR.TO income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -130000.00
DR.TO balance_sheet (quarterly, 2025-03-31) — Working Capital: 35888000.00
DR.TO income_statement (quarterly, 2025-06-30) — +Operating Expense: 41578000.00
DR.TO income_statement (quarterly, 2025-06-30) — +Total Revenue: 80557000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 13795000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 39497000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 470000.00
DR.TO income_statement (quarterly, 2025-06-30) — Amortization: 135000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Amortization Cash Flow: 135000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Amortization Of Intangibles: 135000.00
DR.TO income_statement (quarterly, 2025-06-30) — Amortization Of Intangibles Income Statement: 135000.00
DR.TO income_statement (quarterly, 2025-06-30) — Basic Average Shares: 20645225.00
DR.TO income_statement (quarterly, 2025-06-30) — Basic EPS: 0.24
DR.TO cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 65724000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -1206000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 35216000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Capital Stock: 265221000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 49027000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 49027000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: -1218000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -16922000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -1206000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 1460000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Change In Account Payable: 385000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: 1780000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Change In Inventory: -377000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Change In Payable: 385000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 2165000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 1612000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Change In Receivables: 185000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 3585000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: 185000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Changes In Cash: -16668000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Common Stock: 265221000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Common Stock Dividend Paid: -1218000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 76207000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Common Stock Payments: -7007000.00
DR.TO income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 27001000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 19067000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Current Assets: 99147000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 8067000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Current Debt: 4801000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 12868000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 62585000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: 2177000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Deferred Tax: 2177000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Depreciation: 3880000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 4015000.00
DR.TO income_statement (quarterly, 2025-06-30) — Depreciation Amortization Depletion Income Statement: 4015000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 4015000.00
DR.TO income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 4015000.00
DR.TO income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 3880000.00
DR.TO income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 20645225.00
DR.TO income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.20
DR.TO income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 4631000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Dividends Payable: 1247000.00
DR.TO income_statement (quarterly, 2025-06-30) — EBIT: 13588000.00
DR.TO income_statement (quarterly, 2025-06-30) — EBITDA: 17603000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: -29000.00
DR.TO cash_flow (quarterly, 2025-06-30) — End Cash Position: 49027000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -16922000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 254000.00
DR.TO income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -29000.00
DR.TO income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 37563000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Goodwill: 90600000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 97558000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Gross PPE: 77513000.00
DR.TO income_statement (quarterly, 2025-06-30) — Gross Profit: 53556000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 0.00
DR.TO income_statement (quarterly, 2025-06-30) — Interest Expense: 1772000.00
DR.TO income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 1772000.00
DR.TO income_statement (quarterly, 2025-06-30) — Interest Income: 1694000.00
DR.TO income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 1694000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Interest Paid Cfo: -864000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Inventory: 6481000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Invested Capital: 108624000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -1206000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 27149000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 27616000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 54765000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -3989000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Minority Interest: 24488000.00
DR.TO income_statement (quarterly, 2025-06-30) — Minority Interests: -5008000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -7007000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Net Foreign Currency Exchange Gain Loss: 29000.00
DR.TO income_statement (quarterly, 2025-06-30) — Net Income: 4631000.00
DR.TO income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 4631000.00
DR.TO income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 9639000.00
DR.TO income_statement (quarterly, 2025-06-30) — Net Income Discontinuous Operations: 0.00
DR.TO income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 4631000.00
DR.TO income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 4631000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 9639000.00
DR.TO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 9639000.00
DR.TO income_statement (quarterly, 2025-06-30) — Net Interest Income: -133000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -3989000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -3989000.00
DR.TO income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -133000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -4708000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Net PPE: 77513000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -1206000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -21351000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 21000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 15602000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 21000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 15602000.00
DR.TO income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 17632000.00
DR.TO income_statement (quarterly, 2025-06-30) — Normalized Income: 4654656.99
DR.TO cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 1460000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 29000.00
DR.TO income_statement (quarterly, 2025-06-30) — Operating Income: 11978000.00
DR.TO income_statement (quarterly, 2025-06-30) — Operating Revenue: 80557000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 18857749.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Other Current Borrowings: 4801000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 15608000.00
DR.TO income_statement (quarterly, 2025-06-30) — Other Gand A: 14514000.00
DR.TO income_statement (quarterly, 2025-06-30) — Other Income Expense: -29000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 6958000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 140000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 40592000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Other Properties: 77513000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Other Receivables: 2688000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Payables: 15042000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 34109000.00
DR.TO income_statement (quarterly, 2025-06-30) — Pretax Income: 11816000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -1206000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Raw Materials: 6481000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Receivables: 43639000.00
DR.TO income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 27001000.00
DR.TO income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 4015000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -3989000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: -7007000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -189484000.00
DR.TO income_statement (quarterly, 2025-06-30) — Salaries And Wages: 23049000.00
DR.TO income_statement (quarterly, 2025-06-30) — Selling General And Administration: 37563000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Share Issued: 18857749.00
DR.TO cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 0.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 76207000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -21351000.00
DR.TO income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -5343.01
DR.TO income_statement (quarterly, 2025-06-30) — Tax Provision: 2177000.00
DR.TO income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.18
DR.TO balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 1454000.00
DR.TO cash_flow (quarterly, 2025-06-30) — Taxes Refund Paid: -17261000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Total Assets: 274239000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 103823000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Total Debt: 67633000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 100695000.00
DR.TO income_statement (quarterly, 2025-06-30) — Total Expenses: 68579000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 173544000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 175092000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 110959000.00
DR.TO income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 11978000.00
DR.TO income_statement (quarterly, 2025-06-30) — Total Other Finance Cost: 55000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 0.00
DR.TO income_statement (quarterly, 2025-06-30) — Total Unusual Items: -29000.00
DR.TO income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -29000.00
DR.TO balance_sheet (quarterly, 2025-06-30) — Working Capital: 36562000.00
DR.TO income_statement (quarterly, 2025-09-30) — +Operating Expense: 42019000.00
DR.TO income_statement (quarterly, 2025-09-30) — +Total Revenue: 82561000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 15031000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 40450000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 470000.00
DR.TO income_statement (quarterly, 2025-09-30) — Amortization: 136000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Amortization Cash Flow: 136000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Amortization Of Intangibles: 136000.00
DR.TO income_statement (quarterly, 2025-09-30) — Amortization Of Intangibles Income Statement: 136000.00
DR.TO income_statement (quarterly, 2025-09-30) — Average Dilution Earnings: -3010000.00
DR.TO income_statement (quarterly, 2025-09-30) — Basic Average Shares: 18595164.00
DR.TO income_statement (quarterly, 2025-09-30) — Basic EPS: 0.44
DR.TO cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 49027000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -1092000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 32538000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Capital Stock: 268200000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 46814000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 46814000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: -1247000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -15020000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -1092000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 13917000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 1236000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 92000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Change In Inventory: 154000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Change In Payable: 1236000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 1328000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -450000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Change In Receivables: -953000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 79000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: -953000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Changes In Cash: -2195000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Common Stock: 268200000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Common Stock Dividend Paid: -1247000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 86127000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -5721000.00
DR.TO income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 28377000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 19159000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Current Assets: 97437000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 7225000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Current Debt: 4894000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 12119000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 54403000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: 3057000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Deferred Tax: 3057000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Depreciation: 3759000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 3895000.00
DR.TO income_statement (quarterly, 2025-09-30) — Depreciation Amortization Depletion Income Statement: 3895000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 3895000.00
DR.TO income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 3895000.00
DR.TO income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 3759000.00
DR.TO income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 22064718.00
DR.TO income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.23
DR.TO income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 5117000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Dividends Payable: 1186000.00
DR.TO income_statement (quarterly, 2025-09-30) — EBIT: 18167000.00
DR.TO income_statement (quarterly, 2025-09-30) — EBITDA: 22062000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -18000.00
DR.TO cash_flow (quarterly, 2025-09-30) — End Cash Position: 46814000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -15020000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 12825000.00
DR.TO income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: -18000.00
DR.TO income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 38124000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Goodwill: 90600000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 97422000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Gross PPE: 74601000.00
DR.TO income_statement (quarterly, 2025-09-30) — Gross Profit: 54184000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 0.00
DR.TO income_statement (quarterly, 2025-09-30) — Interest Expense: 2181000.00
DR.TO income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 2181000.00
DR.TO income_statement (quarterly, 2025-09-30) — Interest Income: 6062000.00
DR.TO income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 6062000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Interest Paid Cfo: -1308000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Inventory: 6327000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Invested Capital: 118683000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -1092000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 25313000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 27662000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 52975000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -3750000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Minority Interest: 23960000.00
DR.TO income_statement (quarterly, 2025-09-30) — Minority Interests: -4802000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -5721000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Net Foreign Currency Exchange Gain Loss: 18000.00
DR.TO income_statement (quarterly, 2025-09-30) — Net Income: 8127000.00
DR.TO income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 8127000.00
DR.TO income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 12929000.00
DR.TO income_statement (quarterly, 2025-09-30) — Net Income Discontinuous Operations: 0.00
DR.TO income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 8127000.00
DR.TO income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 8127000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 12929000.00
DR.TO income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 12929000.00
DR.TO income_statement (quarterly, 2025-09-30) — Net Interest Income: 3839000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -2722000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -2722000.00
DR.TO income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 3839000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -5330000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Net PPE: 74601000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -1092000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: -11295000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 27000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 17055000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 27000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 17055000.00
DR.TO income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 22080000.00
DR.TO income_statement (quarterly, 2025-09-30) — Normalized Income: 8141557.86
DR.TO cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 13917000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 18000.00
DR.TO income_statement (quarterly, 2025-09-30) — Operating Income: 12165000.00
DR.TO income_statement (quarterly, 2025-09-30) — Operating Revenue: 82561000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 18343549.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Other Current Borrowings: 4894000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 6908000.00
DR.TO income_statement (quarterly, 2025-09-30) — Other Gand A: 14558000.00
DR.TO income_statement (quarterly, 2025-09-30) — Other Income Expense: -18000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 6822000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: -3889000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 34967000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Other Properties: 74601000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Other Receivables: 3138000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Payables: 16217000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 35376000.00
DR.TO income_statement (quarterly, 2025-09-30) — Pretax Income: 15986000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -1092000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Raw Materials: 6327000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Receivables: 44296000.00
DR.TO income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 28377000.00
DR.TO income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 3895000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -3750000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -5721000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -182543000.00
DR.TO income_statement (quarterly, 2025-09-30) — Salaries And Wages: 23566000.00
DR.TO income_statement (quarterly, 2025-09-30) — Selling General And Administration: 38124000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Share Issued: 18343549.00
DR.TO cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 0.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 86127000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: -11295000.00
DR.TO income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -3442.14
DR.TO income_statement (quarterly, 2025-09-30) — Tax Provision: 3057000.00
DR.TO income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.19
DR.TO balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 708000.00
DR.TO cash_flow (quarterly, 2025-09-30) — Taxes Refund Paid: -864000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Total Assets: 269487000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 113789000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Total Debt: 65094000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 110087000.00
DR.TO income_statement (quarterly, 2025-09-30) — Total Expenses: 70396000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 159400000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 172050000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 104997000.00
DR.TO income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 12165000.00
DR.TO income_statement (quarterly, 2025-09-30) — Total Other Finance Cost: 42000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 0.00
DR.TO income_statement (quarterly, 2025-09-30) — Total Unusual Items: -18000.00
DR.TO income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -18000.00
DR.TO balance_sheet (quarterly, 2025-09-30) — Working Capital: 43034000.00
DR.TO income_statement (annual, 2025-12-31) — +Operating Expense: 130960000.00
DR.TO income_statement (quarterly, 2025-12-31) — +Operating Expense: 6124000.00
DR.TO income_statement (annual, 2025-12-31) — +Total Revenue: 254166000.00
DR.TO income_statement (quarterly, 2025-12-31) — +Total Revenue: 9334000.00
DR.TO balance_sheet (annual, 2025-12-31) — Accounts Payable: 15369000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 15369000.00
DR.TO balance_sheet (annual, 2025-12-31) — Accounts Receivable: 35081000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 35081000.00
DR.TO balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -33759000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -33759000.00
DR.TO balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 470000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 470000.00
DR.TO balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -1049000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -1049000.00
DR.TO income_statement (annual, 2025-12-31) — Amortization: 540000.00
DR.TO income_statement (quarterly, 2025-12-31) — Amortization: 136000.00
DR.TO cash_flow (annual, 2025-12-31) — Amortization Cash Flow: 540000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Amortization Cash Flow: 136000.00
DR.TO cash_flow (annual, 2025-12-31) — Amortization Of Intangibles: 540000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Amortization Of Intangibles: 136000.00
DR.TO income_statement (annual, 2025-12-31) — Amortization Of Intangibles Income Statement: 540000.00
DR.TO income_statement (quarterly, 2025-12-31) — Amortization Of Intangibles Income Statement: 136000.00
DR.TO cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 0.00
DR.TO balance_sheet (annual, 2025-12-31) — Assets Held For Sale Current: 34051000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Assets Held For Sale Current: 34051000.00
DR.TO income_statement (annual, 2025-12-31) — Average Dilution Earnings: 0.00
DR.TO income_statement (quarterly, 2025-12-31) — Average Dilution Earnings: -515000.00
DR.TO income_statement (annual, 2025-12-31) — Basic Average Shares: 19481353.00
DR.TO income_statement (annual, 2025-12-31) — Basic EPS: 1.09
DR.TO cash_flow (annual, 2025-12-31) — Beginning Cash Position: 108496000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 46814000.00
DR.TO balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 41985000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 41985000.00
DR.TO cash_flow (annual, 2025-12-31) — Capital Expenditure: -4879000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -1796000.00
DR.TO balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 28547000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 28547000.00
DR.TO balance_sheet (annual, 2025-12-31) — Capital Stock: 253930000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Capital Stock: 253930000.00
DR.TO balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 43449000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 43449000.00
DR.TO balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 43449000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 43449000.00
DR.TO cash_flow (annual, 2025-12-31) — Cash Dividends Paid: -5091000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Cash Dividends Paid: -1185000.00
DR.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -105454000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -15900000.00
DR.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -4067000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -984000.00
DR.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 45161000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 14029000.00
DR.TO cash_flow (annual, 2025-12-31) — Change In Account Payable: 1828000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 3737000.00
DR.TO cash_flow (annual, 2025-12-31) — Change In Accrued Expense: -1691000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: -41000.00
DR.TO cash_flow (annual, 2025-12-31) — Change In Inventory: -648000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Change In Inventory: -126000.00
DR.TO cash_flow (annual, 2025-12-31) — Change In Payable: 1828000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Change In Payable: 3737000.00
DR.TO cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 137000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 3696000.00
DR.TO cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: 567000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -1774000.00
DR.TO cash_flow (annual, 2025-12-31) — Change In Receivables: -3947000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Change In Receivables: -8965000.00
DR.TO cash_flow (annual, 2025-12-31) — Change In Working Capital: -3891000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -7169000.00
DR.TO cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -3947000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -8965000.00
DR.TO cash_flow (annual, 2025-12-31) — Changes In Cash: -64360000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Changes In Cash: -2855000.00
DR.TO balance_sheet (annual, 2025-12-31) — Common Stock: 253930000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Common Stock: 253930000.00
DR.TO cash_flow (annual, 2025-12-31) — Common Stock Dividend Paid: -5091000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Common Stock Dividend Paid: -1185000.00
DR.TO balance_sheet (annual, 2025-12-31) — Common Stock Equity: 75456000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 75456000.00
DR.TO cash_flow (annual, 2025-12-31) — Common Stock Payments: -63662000.00
DR.TO cash_flow (quarterly, 2025-12-31) — Common Stock Payments: -5149000.00
DR.TO balance_sheet (annual, 2025-12-31) — Construction In Progress: 269000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 269000.00
DR.TO income_statement (annual, 2025-12-31) — Cost Of Revenue: 76548000.00
DR.TO income_statement (quarterly, 2025-12-31) — Cost Of Revenue: -6304000.00
DR.TO balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 15365000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 15365000.00
DR.TO balance_sheet (annual, 2025-12-31) — Current Assets: 122558000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Current Assets: 122558000.00
DR.TO balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 5858000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 5858000.00
DR.TO balance_sheet (annual, 2025-12-31) — Current Debt: 3346000.00
DR.TO balance_sheet (quarterly, 2025-12-31) — Current Debt: 3346000.00
DR.TO balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 9204000.00